Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第5页

Resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany. 雷舒通治疗非肝硬化代谢功能障碍相关脂肪性肝炎伴肝纤维化：在中国、英国、法国和德国建立基于价值的价格。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-14 DOI: 10.1080/14737167.2026.2718421

Andong Li, Meiyu Wu, Yangke Yi, Yongtao He, Chongqing Tan, Xia Luo, Jun Zhang, Xiaomin Wan

{"title":"Resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany.","authors":"Andong Li, Meiyu Wu, Yangke Yi, Yongtao He, Chongqing Tan, Xia Luo, Jun Zhang, Xiaomin Wan","doi":"10.1080/14737167.2026.2718421","DOIUrl":"10.1080/14737167.2026.2718421","url":null,"abstract":"Background: Resmetirom is the first approved pharmacological treatment for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis (F2-F3). We estimated its value-based annual price in China, the United Kingdom, France, and Germany from the health-care payer perspective.Research design and methods: We developed an annual-cycle Markov model for eligible F2-F3 patients receiving standard of care (SoC) or resmetirom plus SoC. Country-specific epidemiology, costs, and willingness-to-pay (WTP) thresholds were applied. Value-based pricing (VBP) was the annual price at which the incremental cost-effectiveness ratio (ICER) equaled the country-specific WTP threshold per quality-adjusted life-year (QALY). Analyses included ICERs at the current US price and probabilistic sensitivity analysis.Results: Resmetirom increased life-years (LYs) by 0.30, 0.71, 0.96, and 0.80 in China, the UK, France, and Germany, with QALY gains of 0.47, 0.96, 1.28, and 1.07. Estimated VBPs were US$3,573, US$6,487, US$9,334, and US$10,656, respectively. At the current US annual price, ICERs exceeded country-specific WTP thresholds in all settings.Conclusions: Price reductions toward country-specific VBPs would be required for resmetirom to be cost-effective in these publicly financed health systems.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns and outcomes in proximal humerus fracture management: a claims-based retrospective analysis of real-world US patient data. 肱骨近端骨折处理的治疗模式和结果：对真实世界美国患者数据的基于索赔的回顾性分析。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-13 DOI: 10.1080/14737167.2026.2717283

Michael Beltran, Jenny Pahys, Jill Ruppenkamp, Katherine Corso, Simone Wolf, Amy Chaya, Nan Tracy Zheng

{"title":"Treatment patterns and outcomes in proximal humerus fracture management: a claims-based retrospective analysis of real-world US patient data.","authors":"Michael Beltran, Jenny Pahys, Jill Ruppenkamp, Katherine Corso, Simone Wolf, Amy Chaya, Nan Tracy Zheng","doi":"10.1080/14737167.2026.2717283","DOIUrl":"10.1080/14737167.2026.2717283","url":null,"abstract":"Background: We evaluated factors associated with open reduction internal fixation (ORIF) and arthroplasty after proximal humerus fractures (PHF) and 12-month reoperation.Methods: A retrospective cohort was created using US healthcare claims from 2016-2025. Multinomial regression assessed factors associated with treatment. Multivariable Cox proportional hazards models evaluated 12-month reoperation risk.Results: Among 250,695 PHF patients, 86% were managed nonoperatively, 11% received ORIF, and 4% received arthroplasty. Among surgically treated patients, arthroplasty utilization increased modestly (24% to 29%), while ORIF declined (76% to 71%). Younger patients and males were more likely to undergo ORIF. Reoperation rates were 7.9% for ORIF and 7.8% for arthroplasty. In patients <54 years, ORIF had lower reoperation rates than arthroplasty (males: 6.84% vs. 13.36%, p = 0.002; females: 6.62% vs.18.24%, p < 0.001); in females aged 65-75, arthroplasty had lower reoperation rates than ORIF (5.39% vs. 7.87%, p < 0.001). Soft tissue (23.3%), mechanical (17.6%), and nonunion (14.1%) complications were observed among ORIF reoperations, versus soft tissue (9.8%) and infection (8.8%) in arthroplasty reoperations.Conclusion: ORIF remains the most common surgery for PHFs, while arthroplasty use increased. Reoperation rates were lower in younger ORIF patients but higher in older females. These findings may inform decision-making for operative treatment for PHFs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing severe gestational hypertension in Italy: a cost description. 在意大利管理严重妊娠期高血压：成本描述。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-13 DOI: 10.1080/14737167.2026.2718416

Carlo Lazzaro, Giovanna Esposito, Anna Cantarutti, Francesco Parazzini, Giovanni Corrao, Matteo Franchi, Fabio Parazzini

{"title":"Managing severe gestational hypertension in Italy: a cost description.","authors":"Carlo Lazzaro, Giovanna Esposito, Anna Cantarutti, Francesco Parazzini, Giovanni Corrao, Matteo Franchi, Fabio Parazzini","doi":"10.1080/14737167.2026.2718416","DOIUrl":"10.1080/14737167.2026.2718416","url":null,"abstract":"Background: Gestational hypertension (GH) is a common complication that affects approximately 5% of pregnancies worldwide.Research design and methods: Presenting a model-based cost description of managing severe GH in inward setting following the Italian National Health Service (INHS) perspective. Epidemiological data on pregnancies and severe GH were obtained from Lombardy region and extrapolated to national level for 2024 (last available year). Health care resources for managing severe GH patients aged 20-49 years, identified and quantified according to literature and expert' opinion, were valued through INHS tariffs (2025 values). One-way and scenario sensitivity analyses tested the robustness of the baseline findings.Results: 375,553 pregnancies and 1928 episodes of severe GH needing hospitalization (0.51% of all pregnancies) were estimated for Italy in 2024. The overall average cost of managing a severe GH episode reaches €752.64. Inward hospitalization (€454.23) is the main cost-driver (60.04% of the total), as confirmed by one-way and scenario sensitivity analyses.Conclusion: As reported in research conducted in other countries, inward hospitalization is both essential and the main cost-driver for the optimal management of severe GH. Outpatient programmes aimed at identifying and following-up GH patients before the disease requires hospitalization should be considered by INHS policymakers.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Principles of selecting cost-effectiveness thresholds in price-taker countries. 在价格接受国选择成本效益阈值的原则。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-12 DOI: 10.1080/14737167.2026.2715977

Zoltán Kaló, Maureen Rutten-van Mölken, Eline Aas, Maximilian Salcher-Konrad, Tomáš Tesař, Tom Belleman, Mirjana Huic, Lucia Masaryková, Zuzana Koblišková, Anne Hendrickx, Bertalan Németh, Ahmad Nader Fasseeh, Carin Uyl-de Groot

{"title":"Principles of selecting cost-effectiveness thresholds in price-taker countries.","authors":"Zoltán Kaló, Maureen Rutten-van Mölken, Eline Aas, Maximilian Salcher-Konrad, Tomáš Tesař, Tom Belleman, Mirjana Huic, Lucia Masaryková, Zuzana Koblišková, Anne Hendrickx, Bertalan Németh, Ahmad Nader Fasseeh, Carin Uyl-de Groot","doi":"10.1080/14737167.2026.2715977","DOIUrl":"10.1080/14737167.2026.2715977","url":null,"abstract":"Introduction: Countries with relatively small market size lack the bargaining power to influence the prices set by pharmaceutical companies, so they function as price-taker rather than price-maker. For price-taker countries, carefully established cost-effectiveness thresholds (CETs) are essential tools to assess local economic value of new medicines.Areas covered: This perspective paper provides an overview of how pharmaceutical price-taker countries may reconsider their CETs. Key aspects of selecting appropriate CETs in price-taker countries include i) the methodology for establishing the main CETs, ii) the selection of factors to modify the baseline CET, if higher spending for one unit of health gain seems justified, and iii) the process of using CETs in policy decisions.Expert opinion: Many academic approaches described in scientific articles are not implemented; the majority of countries establish or make changes in their CETs without strong theoretical foundation. In the next years. several price-taker countries will introduce or update CETs. Lower-income countries, who linked their CETs to the GDP per capita and whose economy has been growing significantly, may reduce their baseline thresholds. There will be significant pressure on higher-income countries to increase their CETs, who did not adjust their CETs for economic growth and/or inflation in recent years.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-level trends in melanoma burden, stage at diagnosis, and indirect costs in Croatia: a descriptive analysis. 克罗地亚黑色素瘤负担、诊断阶段和间接费用的人口水平趋势：一项描述性分析。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-11 DOI: 10.1080/14737167.2026.2715976

Goran Bencina, Marija Buljan, Boris Bencina, Elvira Meni Maria Gkrinia, Andrej Belančić, Petra Turčić

{"title":"Population-level trends in melanoma burden, stage at diagnosis, and indirect costs in Croatia: a descriptive analysis.","authors":"Goran Bencina, Marija Buljan, Boris Bencina, Elvira Meni Maria Gkrinia, Andrej Belančić, Petra Turčić","doi":"10.1080/14737167.2026.2715976","DOIUrl":"10.1080/14737167.2026.2715976","url":null,"abstract":"Background: Croatia has among the highest melanoma mortality rates in the European Union. This study examined temporal trends in melanoma stage at diagnosis, disease burden, and indirect costs in Croatia.Research design and methods: Population-level melanoma incidence data from the Croatian Cancer Registry were analyzed for 2003-2007, 2008-2012, and 2013-2019. Stage distribution and mean annual case numbers were assessed for localized, regional, metastatic, and unknown-stage disease. Disease burden indicators (disability-adjusted life years [DALY], years of life lost [YLL], years lost to disability [YLD]) and indirect costs were evaluated for individuals aged <60 years in 2000, 2010, and 2019. Analyses were descriptive; no formal statistical testing was performed.Results: Localized melanoma rose from 55% to 68%, while metastatic disease declined from 17% to 8%. Mean annual localized cases more than doubled, whereas metastatic case counts remained stable. DALYs and YLLs decreased by 19% and 21%, respectively, while YLDs increased. Annual indirect costs declined, with cost savings of €8.3 million (DALY method) and €8.4 million (YLL method).Conclusions: Declining DALYs, YLLs, and indirect costs suggest improving melanoma outcomes in Croatia, potentially reflecting earlier detection and therapeutic innovation, and underscore the importance of sustained investment in integrated melanoma control strategies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer's disease based on drug selection recommendations for Chinese medical institutions. 基于我国医疗机构药物选择建议的胆碱酯酶抑制剂治疗阿尔茨海默病的综合评价

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-11 DOI: 10.1080/14737167.2026.2715983

Jieqiong Lv, Xianbin Cai, Zhaopeng Yang, Bin Li, Yanqiong Zhou, Fenge Li, Hongbo Fu

{"title":"A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer's disease based on drug selection recommendations for Chinese medical institutions.","authors":"Jieqiong Lv, Xianbin Cai, Zhaopeng Yang, Bin Li, Yanqiong Zhou, Fenge Li, Hongbo Fu","doi":"10.1080/14737167.2026.2715983","DOIUrl":"10.1080/14737167.2026.2715983","url":null,"abstract":"Background: Cholinesterase inhibitors (ChEIs) are widely used to treat Alzheimer's disease (AD), yet the optimal choice remains unclear.Research design and methods: This study aimed to comprehensively evaluate the overall clinical value of seven ChEI formulations to provide evidence‑based guidance for rational AD pharmacotherapy selection. We constructed an evaluation framework based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition), which combined mini‑health technology assessment with the System of Objectified Judgment Analysis (SOJA). Seven formulations were assessed across five weighted dimensions: pharmacological properties, efficacy, safety, economy, and other attributes. A systematic literature search was performed using PubMed, CNKI, Wanfang, and official regulatory databases.Results: Within this assessment framework, donepezil tablets achieved the highest score (74.86), followed by rivastigmine patches (73.50) and rivastigmine capsules (72.28). These three formulations are recommended as priority options for inclusion in Chinese hospital formularies. The remaining four drugs may be prescribed according to individual patient conditions and available institutional resources.Conclusions: This study provides evidence‑based guidance for clinical and institutional decision‑making in AD management and delivers a generalizable assessment framework adaptable to local real‑world data for healthcare institutions globally.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-16"},"PeriodicalIF":2.2,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020-2025). 监管审批趋势和市场准入影响：新药和补充药物申请的多区域比较框架（2020-2025）。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-10 DOI: 10.1080/14737167.2026.2715979

Mohit Bajaj, Mital Patel

{"title":"Regulatory approval trends and market access implications: a multiregional comparative framework for new and supplemental drug applications (2020-2025).","authors":"Mohit Bajaj, Mital Patel","doi":"10.1080/14737167.2026.2715979","DOIUrl":"10.1080/14737167.2026.2715979","url":null,"abstract":"Background: Drug approval remains fragmented, governed by region-specific regulatory frameworks and review pathways. Despite international harmonization, the same product is often approved at different timelines and under different pathways across regions, complicating regulatory planning. Currently, there is no unified system that enables concurrent comparison of multiregional drug approvals.Methods: Drug Approvals in the US, EU, Japan, and India were evaluated from Jan-2020 to June-2025. NDA approvals were assessed year-wise, review type, and by pharmacotherapeutic area to identify key focus areas. Supplemental approvals were analyzed year-wise, application categorywise, and by therapeutic area to understand post-approval patterns. This study analyses multiregional approval trends and addresses this gap through an integrated analytical framework. To enable integrated multiregional assessment, a web-based regulatory intelligence dashboard was developed.Results: The dashboard consolidates approval data across regions and parameters into a harmonized interface for simultaneous visualization, comparison and assessment across multiple jurisdictions. For pharmaceutical manufacturers, the availability of such a platform enables monitoring of approval patterns, identifying unapproved or underexplored markets and supporting data-driven strategic planning for earlier market access. The dashboard provides regulatory authorities, sponsors, researchers and policy makers consolidated visibility into cross-regional activity.Conclusion: Overall, the dashboard enables data-driven comparison by addressing a gap in existing information systems.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors associated with renewal outcomes for anti-cancer drugs in China's national reimbursement drug list negotiation: a retrospective observational study. 中国国家药品报销目录谈判中与抗癌药物续期结果相关的因素：一项回顾性观察研究

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-08-10 DOI: 10.1080/14737167.2026.2715984

An-Ping Guo, Hai-Liang Guo, Zhen-Zhen Pan, Han-Lu Zhang, Xiao-Ke Zhang, Xue-Qin Wang

{"title":"Factors associated with renewal outcomes for anti-cancer drugs in China's national reimbursement drug list negotiation: a retrospective observational study.","authors":"An-Ping Guo, Hai-Liang Guo, Zhen-Zhen Pan, Han-Lu Zhang, Xiao-Ke Zhang, Xue-Qin Wang","doi":"10.1080/14737167.2026.2715984","DOIUrl":"10.1080/14737167.2026.2715984","url":null,"abstract":"Background: Price negotiation improves access to innovative anti-cancer drugs in China but pressures healthcare funds. Renewal negotiation balances cost and access, with success defined as entering a new 2-year agreement after initial term. This study analyzes renewal factors from innovation and price adjustment dimensions.Research design and methods: We analyzed 104 anti-cancer drugs (2017-2023) using a multivariate logistic regression model with five prespecified variables from two policy-relevant dimensions (innovation and price adjustment). Adopting Bootstrap validation (1000 resamples) to assess overfitting and estimation stability. Stratified analyses were performed by innovation category.Results: Sixty-eight drugs were renewed. With five variables, EPV was 13.6. Exclusivity and priority review status were positively associated with renewal success from the innovation dimension. Indication expansion showed positive but non-significant association. Initial price reduction and first price reduction showed positive association from the price adjustment dimension. Bootstrap-corrected AUC was 0.856. Stratified analyses showed 52.9% of First-in-class (FIC) drugs renewed without price reduction or indication expansion, whereas non-FIC drugs required these measures.Conclusions: Exclusivity, priority review status, and price reduction measures are positively associated with renewal success. Stratified analyses suggest that FIC drugs may receive greater policy tolerance, whereas non-FIC drugs appear to require price reductions or indication expansion.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluations of assisted reproductive technologies (ART) for specialized infertility treatment: a systematic review of IVF, IUI and ICSI. 辅助生殖技术（ART）用于特殊不孕症治疗的经济评价：IVF， IUI和ICSI的系统综述。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-07-22 DOI: 10.1080/14737167.2026.2694563

Mehdi Khakian, Aghdas Souresrafil, Farahnaz Farzaneh, Aziz Rezapour

{"title":"Economic evaluations of assisted reproductive technologies (ART) for specialized infertility treatment: a systematic review of IVF, IUI and ICSI.","authors":"Mehdi Khakian, Aghdas Souresrafil, Farahnaz Farzaneh, Aziz Rezapour","doi":"10.1080/14737167.2026.2694563","DOIUrl":"https://doi.org/10.1080/14737167.2026.2694563","url":null,"abstract":"Introduction: Couples suffering from infertility range between 10 and 15% worldwide. As assisted reproductive technologies revolutionize treatment, this systematic review synthesizes economic evaluations of these ART methods to identify cost-effective ones.Methods: A search of the PubMed, Embase, Web of Science, Scopus databases and Google Scholar was conducted from 1990 to 2024 to find full economic analyses studies of IVF, IUI, and ICSI. Comparing at least two ART methods for infertile couples or strategies within amethod is one of the incl usion criteria. Qualitative descriptions and summaries provided concerning the cost-effectiveness of all interventions. A comprehensive narrative synthesis of the data developed. This categorized based on the type of intervention.Results: A total of 102 studies were included, mostly from CEAs. In cases of poor prognosis, IVF is the most cost-effective treatment option, while IUI is the most cost-effective in cases of mild prognosis. While ICSI is not recommended routinely for non-male factor infertility, it is an effective treatment for severe male factor infertility. Age and etiology were identified as key factors influencing the cost-effectiveness results.Conclusion: Prognosis-based strategies (such as IUI first for mild cases, selective ICSI) are more cost effective.Registration: PROSPERO (CRD420251242666).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH. MASH的经济负担：可能MASH患者、未MASH患者和确诊MASH患者的医疗资源利用和成本比较

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-07-16 DOI: 10.1080/14737167.2026.2692644

Caichen Zhong, Nana Boame, Semiu O Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E Rinella

{"title":"The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.","authors":"Caichen Zhong, Nana Boame, Semiu O Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E Rinella","doi":"10.1080/14737167.2026.2692644","DOIUrl":"10.1080/14737167.2026.2692644","url":null,"abstract":"Background: This retrospective study compared healthcare resource utilization (HCRU) and costs between patients with probable metabolic dysfunction-associated steatohepatitis (MASH) and those without MASH or those with diagnosed MASH in the United States.Research design and methods: Patients from Komodo Healthcare Map data (2017-2022) were divided into 3 groups: probable MASH (hepatic steatosis index >36 or ICD-10-CM K76.0 plus ≥1 cardiometabolic risk factor), diagnosed MASH (ICD-10-CM K75.81), and without MASH (none of the aforementioned characteristics). Propensity score weighting adjusted for baseline differences. HCRU and costs were calculated for all-cause, major adverse liver outcomes (MALO), and major adverse cardiovascular events (MACE).Results: Patients with probable MASH (n = 1 549 485) had higher all-cause, MALO-related, and MACE-related HCRU than those without MASH (n = 513 862). However, patients with probable MASH had lower HCRU than those with diagnosed MASH (n = 15 000). Associated costs per patient per year were higher in patients with probable MASH vs those without MASH (rate ratio, 1.27; 95% CI, 1.26-1.28), but lower than in patients with diagnosed MASH (rate ratio, 0.70; 95% CI, 0.67-0.72).Conclusions: HCRU and costs were higher in patients with probable MASH than in patients without MASH. Results highlight the economic burden associated with probable MASH and the importance of early diagnosis.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0